| 영문 | wound infection | 한글 | 상처감염 |
|---|---|---|---|
| 설명 | 절손 등의 기계적 상해, 인위적 부상 또는 타균의 침입에 의해 상처난 조직에서 침입하여 감염시키는 것. |
||
| 영문 | neonatal intensive care center | 한글 | 신생아 집중치료실 |
|---|---|---|---|
| 설명 | 미숙아나 가사 상태의 출산아를 집중적으로 보살피고 치료하는 기관. |
||
| 영문 | intensive care unit | 한글 | 중환자실 |
|---|---|---|---|
| 설명 | 병세나 상처 따위의 정도가 매우 심한 사람을 치료하고 돌볼 수 있도록 마련한 방. 호흡-순환-대사 등 정신적 급성기능상실의 환자를 취급하며 강력하고도 집중적인 진료를 하는 부분이다. 위독한 환자에 대하여는 24시간 체제로 대응한다. 충분히 훈련을 받은 의료진이 배치되며 기능적으로 설비가 갖추어져 있다. 심근경색증-호흡기능상실-콩팥기능상실-소아-신경외과계 등 특정환자를 대상으로 한다. |
||
| 영문 | gunshot wound | 한글 | 총상 |
|---|---|---|---|
| 설명 | 총기류에 의해 상처를 입은 것. 라이플-권총-공기총 등의 탄환에 의한 상처-탄환에 충분한 힘이 있으면 몸을 관통하여 관통총창이 되지만, 그렇지 못할 경우에는 총탄이 체내에 머물러 맹관총창이 된다. 따라서, 전자에서는 사입공(총알이 들어간 부위)과 사출공(총알이 나간 부위)가 있고, 후자에는 사입공만 있다. 일반적으로 사입공은 작고 그 테두리가 깨끗하지만 사출공은 피부가 파열되어 구멍이 크므로 곧 구별된다. 가까이서 맞은 자는 사입구 부근에 화약에 의한 탄소가 부착되어 있는 것을 볼 수 있다. 또 사입구 안쪽에는 옷의 헝겊조각 등이 눌려져 있는 수도 있다. 손상은 대체로 사입구와 사출구를 연결하는 길에 있는 장기 조직에 일어난다. 맹관총창에서는 탄환이 체내에 머무는데, 통과한 조직장기를 손상시키는 것은 관통총창과 같다. |
||
| 영문 | oral administration | 한글 | 경구복용 |
|---|---|---|---|
| 설명 | 약을 투여하는 방법에는 여러 가지가 있다. 크게 나누어 보면, 입을 거쳐 위창자계를 통해 넣는 방법과 위창자계를 통하지 않고 바로 혈액으로 넣는 방법이 있다. 위창자계를 통하지 않는 방법으로 가장 흔한 방법은 주사를 이용하는 방법이다. 하지만, 이외에 항문을 통해 넣는 좌약식방법과 혀밑에 넣는 혀밑투여법도 있다. 그러나 대부분의 약제는 경구복용을 하게 된다. 경구복용에 대한 약자는 p.o.(per oral)로 표기한다. 경구복용제의 단점은 복용한 약제가 위창자관계를 거치면서 사람마다 각기 다른 흡수정도와 대사정도를 거치게 되므로 일정한 농도유지가 어렵다는데 있다. 또한 경구복용제의 모양이 캡슐형인지, 혹은 가루형인지에 따라서도 같은 약이지만, 서로 다른 효과를 나타낼 수 있다. |
||
| FDP(s) | 1) Fibrinolytic split Products(= FSP) 2) Fibrinogen Degradation Products |
|---|---|
| FSP | familial spastic paraplegia; fibrin split products; fibrinogen split products; fine suspended partic... |
| ORS | olfactory reference syndrome; oral rehydration solution; oral surgery, oral surgeon; Orthopaedic Res... |
| SW | seriously wounded; short waves; sinewave; slow wave; soap and water; social worker; spike wave; spir... |
| CCC | care-cure coordination; cathodal closure contraction; chronic calculous cholecystitis; chronic catar... |
| SWI | Surgical Wound Infection |
|---|---|
| WBS | Wound breaking strength |
| AGE | Advanced Glycation End Products |
| AGE | Advanced Glycosylated End-products |
| CPMP | Committee for Proprietary Medicinal Products |
| biological products | Complex pharmaceutical substances, preparations, or agents of organic origin, usually obtained by biological methods or assay, that depend for their action on the processes affecting immunity. They are used especially in diagnosis and treatment of disease (as vaccines or pollen extracts). Biological products are differentiated from biological factors in that the latter are compounds with biological or physiological activity made by living organisms. (12 Dec 1998) |
|---|---|
| blood products | Biopharmaceutical products purified from human blood, such as the blood clotting factor VIII used to treat haemophiliacs. (Recombinant factor VIII is also on the market.) The term also refers to biopharmaceuticals that act on blood or the cells that make blood. These products are often produced by the cells themselves, but in such tiny amounts that extracting them from blood is impractical, and so they are genetically engineered. (14 Nov 1997) |
| gene products, env | Retroviral proteins, often glycosylated, coded by the envelope (env) gene. They are usually synthesised as protein precursors (polyproteins) and later cleaved into the final products by a viral protease. (12 Dec 1998) |
| gene products, gag | Proteins coded by the retroviral gag gene. The products are usually synthesised as protein precursors or polyproteins, which are then cleaved by viral proteases to yield the final products. Many of the final products are associated with the nucleoprotein core of the virion. Gag is short for group-specific antigen. (12 Dec 1998) |
| gene products, nef | Products of the HIV nef gene (formerly 3'-orf gene). The products trans-suppress viral replication and function as negative regulators of transcription. Nef stands for negative factor. (12 Dec 1998) |
| gene products, pol | Retroviral proteins coded by the pol gene. Often synthesised as a gag-pol fusion protein (fusion proteins, gag-pol) and later cleaved into final products that include reverse transcriptase, endonuclease/integrase, and viral protease. Pol is short for polymerase, the enzyme class of reverse transcriptase. (12 Dec 1998) |
| gene products, rev | Trans-acting nuclear proteins whose functional expression are required for HIV viral replication. Specifically, the rev gene products are required for processing and translation of the HIV gag and env mRNAs, and thus rev regulates the expression of the viral structural proteins. Rev can also regulate viral regulatory proteins. A cis-acting antirepression sequence (car) in env, also known as the rev-responsive element (rre), is responsive to the rev gene product. Rev is short for regulator of virion. (12 Dec 1998) |
| gene products, rex | Post-transcriptional regulatory proteins required for the accumulation of mRNAs that encode the gag and env gene products in HTLV-I and HTLV-II. The rex (regulator x; x is undefined) products act by binding to elements in the ltr. (12 Dec 1998) |
| gene products, tat | Trans-acting transcription factors. Nuclear proteins whose expression is required for HIV viral replication. The tat protein stimulates HIV-ltr-driven RNA synthesis for both viral regulatory and viral structural proteins. Tat stands for trans-activation of transcription. (12 Dec 1998) |
| gene products, tax | Transcriptional trans-acting proteins of the promoter elements found in the long-terminal repeats (ltr) of HTLV-I and HTLV-II. The tax (trans-activator x; x is undefined) proteins act by binding to enhancer elements in the ltr. (12 Dec 1998) |
| gene products, vif | A 23 kD regulatory protein important for virion infectivity in HIV. The protein is found in the cytoplasm of HIV-infected cells and is not absolutely required for virion formation. (12 Dec 1998) |
| gene products, vpr | Trans-acting proteins which accelerate virus replication in HIV. The vpr proteins act in trans to increase the levels of HIV specified proteins. Vpr is short for viral protein r, where r is undefined. (12 Dec 1998) |
| gene products, vpu | Non-glycosylated, membrane-associated, 16 kD proteins which are expressed in large amounts in cells infected with HIV-1. The proteins are required for efficient virion maturation and release. They are not present in HIV-2 nor in siv. Vpu is short for viral protein u, with u undefined. (12 Dec 1998) |
| meat products | Articles of food which are derived by a process of manufacture from any portion of carcasses of any animal used for food (e.g., head cheese, sausage, scrapple). (12 Dec 1998) |
| glycosylation end products, advanced | Products derived from the nonenzymatic reaction of glucose and proteins in vivo that exhibit a yellow-brown pigmentation and an ability to participate in protein-protein cross-linking. These substances are involved in biological processes relating to protein turnover and it is believed that their excessive accumulation contributes to the chronic complications of diabetes mellitus. (12 Dec 1998) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|